Provectus Biopharma (PVCT) Receives Rose Bengal Analogs-Related U.S. Patent

August 23, 2016 6:03 AM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Provectus Biopharmaceuticals, Inc. (NYSE: PVCT) announced that it has received a U.S. patent covering additional aspects of its process for synthesizing halogenated xanthenes, the family of compound to which rose bengal belongs. The patent covers use of certain halogenated xanthenes in pharmaceutical compositions and as medicaments.

Eric Wachter, CTO of Provectus, noted, "U.S. Patent No. 9,422,260 covers claims that we announced in mid-July had been allowed by the U.S. Patent and Trademark Office. It covers subject matter included in the original, 'parent' case that led to issuance of U.S. Patent 8,530,675 in September 2013, covering our novel process for synthesizing rose bengal and related analogs. This ‘daughter’ patent extends protection to use of a wide range of those analogs in or as therapeutic products, and provides complementary protection to that afforded by the parent patent."

Wachter added, "The daughter patent provides a significant potential commercial lifetime for these analogs. Along with U.S. Patent No. 9,273,022, issued earlier this year and also derived from the original parent case, the new patent expands our ability to control the supply chain for rose bengal and related analogs for use in PV-10, PH-10 and possible successor products.”

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Litigation, Management Comments

Add Your Comment